High risk of renal outcome of metabolic syndrome independent of diabetes in patients with CKD stage 1–4: The ICKD database
Sign Up to like & getrecommendations! Published in 2023 at "Diabetes/Metabolism Research and Reviews"
DOI: 10.1002/dmrr.3618
Abstract: To investigate whether metabolic syndrome (MetS) could predict renal outcome in patients with established chronic kidney disease (CKD). read more here.
Keywords: renal outcome; metabolic syndrome; high risk; outcome metabolic ... See more keywords
Anti-nucleosome antibodies increase the risk of renal relapse in a prospective cohort of patients with clinically inactive systemic lupus erythematosus
Sign Up to like & getrecommendations! Published in 2020 at "Scientific Reports"
DOI: 10.1038/s41598-020-69608-5
Abstract: An important goal in the management of systemic lupus erythematosus (SLE) is the prediction of relapses. This study assesses whether anti-nucleosome antibodies (anti-NCS) increase the risk of renal relapse in inactive SLE. A prospective cohort… read more here.
Keywords: anti ncs; risk renal; relapse; inactive sle ... See more keywords
The risk of renal comorbidities in celiac disease patients depends on the phenotype of celiac disease
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Internal Medicine"
DOI: 10.1111/joim.13532
Abstract: An increased risk of kidney disease in patients with celiac disease has been reported, but the association has remained obscure. Only few studies have investigated the association between renal comorbidities and dermatitis herpetiformis, a cutaneous… read more here.
Keywords: disease patients; celiac disease; disease; renal comorbidities ... See more keywords
A systematic review and combined analysis of phase III trials to evaluate the safety of adjuvant sunitinib in patients with high risk renal cell carcinoma after nephrectomy.
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.34_suppl.214
Abstract: 214 Background: Sunitinib, an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor, has been approved in adjuvant treatment of high risk renal cell carcinoma (RCC) after nephrectomy despite distinct results among studies, along… read more here.
Keywords: phase; risk; adjuvant sunitinib; high risk ... See more keywords